Assessment of the impact of Rivaroxaban in peripheral artery disease (PAD) of the lower extremities

Phase 2

Recruiting

• Conditions: Peripheral vascular disease, unspecified; I73.9; Peripheral artery disease (PAD) of the lower extremities.

• Registration Number: IRCT20231117060086N1
• Lead Sponsor: Ahvaz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 112

Inclusion Criteria

Patients with peripheral artery disease (PAD) of the lower extremities who underwent endovascular revascularization
Age above 50 years

Exclusion Criteria

Clinical need for systemic anticoagulation

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Status of Pain and lameness. Timepoint: Patients will be followed up for a visit one week, one month, three months and six months after starting the medication. Method of measurement: Clinical examination.

Secondary Outcome Measures

Name	Time	Method
Status of heart attack, ischemic stroke, cardiovascular death, acute limb ischemia and limb amputation due to vascular causes. Timepoint: Patients will be followed up for a visit one week, one month, three months and six months after starting the intervention. Method of measurement: Clinical examination.